With $15 million in cash, about $12 million in annual operating cash flow and the potential for $25 million from warrants conversions, Tianyin has the war chest to pursue accretive acquisitions that may give upside to guidance. Bullish commentary from a recent press release elaborates on the Company's view which emphasizes that
"commercializing and broadening our product line coupled with the expansion of our production facility and capacity should continue to yield significant increases in revenue in 2010 and beyond."
While short-term investors may still approach TPI with trepidation, astute long-term investors may be begin to notice the opportunity, especially given the company's overall strong fundamental story. The stock is trading at a forward P/E of 8 on our implied EPS guidance of 50 cents per share.
(BSPM - Get Report) is another pharmaceutical company whose stock we own. In our interview with management, BSPM demonstrated that it has a coherent understanding of its markets and the steps necessary to accelerate growth.
Biostar manufactures and distributes 15 nonprescription, prescription and nutraceutical products.